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Abstract
Objective: Characterisation of anticoagulant control is fundamental to investigations of its association with clinical
outcome. Anticoagulant control depends on several factors. This paper aims to illustrate the implications of different
methods for measuring and analysing anticoagulant control in patients with second generation mechanical heart valve
prostheses.
Methods: International normalised ratio (INR) data collected during the 10-year follow-up of a randomised controlled trial
were analysed. We considered the influence of: 3 different target INR ranges; anticoagulant control expressed as the
proportion of INR readings (PoR) vs. anticoagulant control follow-up time (PoT); 3 ways of describing the profile of
anticoagulant control over time.
Results: Different target INR ranges dramatically influenced derived measures of anticoagulant control; the PoT within the
target range varied from 88% for the widest to 28% for narrowest range. Overall distributions of PoR and PoT observations
were similar but differed by up to 620% for individuals; PoT exceeded PoR when control was good but was less than PoR
when control was poor. Classifying PoT outside the target range showed that widely varying combinations of PoT too high
and too low are possible across individuals.
Conclusions: Researchers’ choices about methods for measuring and quantifying anticoagulant control markedly influence
the values derived from INR readings. The use of different methods across studies makes it difficult or impossible to
compare findings and to establish an evidence base for clinical practice. Methods for quantifying anticoagulant control
should be standardised.
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Introduction
Patients with mechanical heart valve prostheses are maintained
on lifelong anticoagulation to reduce the risks of systemic
thromboembolism and valve thrombosis. The international
normalised ratio (INR) is widely used to provide a reliable
standardised measure of anticoagulant control [1]. Anticoagula-
tion also poses an iatrogenic risk to health from haemorrhage and
it is important to maintain a level of anticoagulation that
minimises the combined thromboembolic and haemorrhagic risks.
Interest in optimising the level of anticoagulant control has led
to research studies of the association between anticoagulant
control and clinical outcome [2–10]. Characterising anticoagulant
control is fundamental to such studies and depends on several
factors:
A. Definition of target INR range: In a clinical population, it is
not feasible to analyse anticoagulant control as a continuously
varying quantity (i.e. INR) over time. Therefore, researchers
have tended to derive aggregate measures of anticoagulant
control, such as the proportion of follow-up time during
which a patient’s INR was within a specified target range.
This percentage depends critically on the target range
adopted.
B. The method used to measure anticoagulant control: Azar et
al. [11] described several alternatives that have been used by
researchers to translate INR readings at discrete time points
into a measure of anticoagulant control.
C. The method of describing the profile of anticoagulant control
over time: many studies have described anticoagulant control
by deriving some measure of the extent to which a patient’s
INR was within a specified target range during follow-up.
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However, the consequences of being outside the target range
may differ depending on (a) the proportion of time during
which a patient’s INR was too high or too low during follow-
up and (b) the extent to which the INR diverged from the
target range. Two patients with the same proportion of
follow-up time within the target range could have very
different profiles of time out of control, e.g. one mainly high,
the other mainly low, potentially with different clinical
consequences; similarly, two patients with the same propor-
tion of follow-up within the target range could have INR
levels which diverged from the target range to a greater or
less extent when outside the target range.
D. The method of analysis: Anticoagulant control can be
characterised across all available follow-up, or as a ‘time
varying’ measure (multiple measures of anticoagulant control
determined for different periods of follow-up, e.g. 6 monthly
or annually).
Any attempt to characterise anticoagulation control involves a
compromise. Measurements of anticoagulation using INR are
subject to inter-individual biological variation in the plasma levels
of coagulation factors (for a given INR) and to imprecision in INR
measurement in the laboratory. INR can also vary within
individual patients over time due to fluctuations in dietary vitamin
K, drug interactions or poor compliance.
The aim of this paper is to illustrate how decisions about factors
A-D can have important implications for the characterisation of
anticoagulant control and, hence, for studies that aim to measure
anticoagulant control or investigate associations between antico-
agulant control and outcome. We also report a new categorical
‘profile’ measure of anticoagulant control to characterise the
predominant nature of the deviation when a patient is not well
controlled.
Methods
Data from an existing randomised controlled trial (RCT)
comparing two second generation mechanical bileaflet heart
valves, St Jude Medical and Carbomedics, were used to illustrate
the consequences of different decisions about factors A, B and C.
Details of the methods of this study, and 5 and 10 year follow-up
with respect to mortality and valve-related events (the key
outcomes in the RCT), have been reported previously [12,13].
No difference in outcome between valves was observed [12,13]
and the analyses reported in this paper treat patients from both
arms of the trial as a single cohort. The trial was approved by a
UK National Health Service Research Ethics Committee.
Anonymised data were analysed for this paper.
The cohort was divided into two groups; (a) participants who
had an aortic valve replacement only (AVR) and (b) participants
who had a mitral valve replacement with or without an aortic
valve replacement (MVR).
Description of follow-up methods
Follow-up information was obtained by an annual questionnaire
to survivors (by telephone), requesting participants to provide the
last 10 INR readings for the year of follow-up (from their
anticoagulant history booklet filled out by the physician), and
details of any thromboembolic or bleeding events requiring
hospitalisation. Participants who did not send back their
questionnaires were sent a reminder and were then telephoned.
Clinical events were clarified by contacting the participant’s family
physician or hospital cardiologist when there was uncertainty
about the details of the event.
When INR readings were unstable or out-of-range, it is likely
that more frequent measurements were taken until the INR was
back in-range. There may also have been periods when
anticoagulation might have been suspended or reversed for a
surgical procedure or serious bleeding. Even in such cases the last
10 INR readings available from the patient diary were used, to
avoid restricting the variability of anticoagulation control when
patients’ ongoing management or other circumstances may have
caused the INR to become unstable.
Factor A: Definitions of target INR ranges
The RCT on which analyses in this paper are based was carried
out between 1992 and 2004. During this time, three target INR
ranges were being recommended in guidelines and are likely to
have directed anticoagulation for trial participants:
I: 2.0 to 4.0 [3];
II: 2.5 to 3.5 [14];
III: 2.5 to 3.0 for the AVR group and 3.0 to 3.5 for the MVR
group [15].
Since the trial concluded, more recent recommendations have
been made [16] and usual practice has tended to use lower INR
ranges, largely based on observational evidence that lower INR
values are safe. We have nevertheless carried out the analyses with
the above INR ranges because they are contemporary for the
period of the trial and allow us to illustrate the consequences of
adopting different ranges.
Factor B: Measures of anticoagulant control
We investigated two ways of measuring anticoagulant control,
namely the proportion of follow-up INR readings [3] and the
proportion of follow-up time, when the INR was within the
specified target range, too low or too high. When calculating the
proportion of follow-up time, the INR level was interpolated on a
daily basis from the dates on which INR readings were available
[11]. Other measures exist [11] but were not considered here.
The first method expresses the proportion of INR readings
within the defined target range as a proportion of all INR readings
during follow-up, providing $10 INR readings are available. This
measure is abbreviated here to ‘percentage of readings’ in control,
too low or too high (PoRin control, PoRtoo low. PoRtoo high). It has
been reported to give the lowest estimates of anticoagulant control
[11]. The method takes no direct account of time under
observation, unless INR readings are assumed to be available at
constant intervals for all patients under observation for the entire
duration of follow-up.
The second method is based on interpolating anticoagulant
control on a day-to-day basis, assuming that the INR level changes
linearly between readings. Anticoagulant control is expressed as a
‘percentage of time’ (PoTin control, PoTtoo low. PoTtoo high). If gaps
in time between readings are longer than 56 days, these periods of
time do not contribute to PoTin control for individual patients.
(There were gaps of this kind during follow-up for our dataset
because the last ten sequential INR readings provided by patients
often did not cover a full year; Figure S1.)
Factor C: Describing the profile of anticoagulant control
over time
As well as calculating the PoTin control for different target INR
ranges, we divided the time out of control into the PoT when the INR
was too low (PoTtoo low) and too high (PoTtoo high). PoTin control,
PoTtoo high and PoTtoo low are correlated because they must sum to
the total eligible follow-up time.
Methods to Describe Anticoagulant Control
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In order to describe the profile of anticoagulant control for
individual patients, we created four mutually exclusive categories
based on PoTin control, PoTtoo high and PoTtoo low:
N Good: PoTin control$67%
N Fair: (PoTin control,33%) AND (PoTtoo low$33%) AND
(PoTtoo high$33%)
N Too high: (PoTtoo high$33%) AND (PoTtoo low,33%)
N Too low: (PoTtoo low$33%) AND (PoTtoo high,33%)
Fair control describes INR outside the target range most of the
time but approximately centred on the target range, with roughly
equal PoTtoo low and PoTtoo high. ‘Too high’ and ‘too low’
represent INR predominantly high or low, respectively, when out
of range.
We also divided the distribution of observations of PoTin control
in two ways, to create two ordinal measures of anticoagulant
control, each with four levels:
N four groups with equal numbers of observations (i.e. quartiles
of the distribution);
N four groups of equal width defined according to the PoTin control
(i.e. 0–24%, 25–49%, 50–74%, 75–100%).
We created ordinal variables for the PoTtoo high and PoTtoo low
in the same way. Like the profile measure, these ordinal measures
of PoTin control, PoTtoo high and PoTtoo low collectively characterise
the predominant deviation in an individual when the INR is not in
control but require three variables to be inspected rather than one.
(Strictly, only two of the three variables need to be examined
because the third can be derived from the other two.)
We calculated all measures of anticoagulant control both for the
entire duration of follow-up for a participant and annually for full
or part-years of follow-up. The means/medians of the distributions
for overall and annual measures will be similar if anticoagulant
control does not change systematically over time. However, the
distribution of the overall measure will inevitably be less dispersed
because outlying annual observations will be smoothed when
combined over all years of follow-up.
Statistical analysis
Cumulative frequency distributions of PoRin control and PoTin
control were generated and summarised graphically for different
target INR ranges. Discrepancies between overall measures of
PoRin control and PoTin control were illustrated by Bland-Altman
limits of agreement plots [17]. Changes in categorisation of
anticoagulant control over successive years were summarised as
cross tabulations. Our aim was purely descriptive and we did not
use statistical hypothesis tests except when examining the
relationships between differences and averages in Bland-Altman
plots. All analyses were carried out using STATA v12.1 (Stata
Corporation, Texas).
Results
Study population
Details of the study population have been described elsewhere
[12,13]. Participants (n = 485) were recruited from 1992 to 1996;
69 who provided ,10 INR readings are excluded from the
analyses. INR data for the remaining 416 were available at latest
up to 31 December 2004 when data collection stopped. The total
observation time for these 416 participants was 3,499 patient
years.
Patients with insufficient INR data were more likely to have
died during follow-up (57/69, 82.6%; 32/42 in the AVR group
and 25/27 in the MVR group) than patients with adequate INR
data (108/416, 26.0%; 49/247 in the AVR group and 59/169 in
the MVR group). Similar percentages of patients in AVR and
MVR groups had insufficient INR data for analysis (AVR, 42/
289, 14.5%; MVR, 27/196, 13.8%). Only 16 of 108 deaths during
follow-up were valve related.
Of 416 participants who had $10 INR readings during follow-
up, there were 247 in the AVR group and 169 in the MVR group.
A total of 27,383 unique, valid INR readings were documented in
these patients; 110 did not have dates and were excluded. A total
of 23,946 INR readings (87.8% of 27,273) occurred within 56 days
after the preceding measurement. The median gap between
measurements was 21 days (inter-quartile range 13 to 30 days; see
Figure S1) with a distribution that reflected scheduling of
measurements at weekly intervals; the distribution did not differ
by AVR/MVR group (Figure S1, b&c). The other 3,327 INR
readings which occurred more than 56 days after the preceding
measurement caused gaps in the INR record; these gaps arose
mainly (65% of 3,327) because of periods of time between
sequences of 10 readings recorded for different years of follow-up.
The median duration of follow-up was 9.0 years and the median
number of INR readings per participant was 77 (range 10 to 110).
The cumulative frequency distributions of all INR readings were
very similar for the AVR and MVR groups; medians, 75th and
99th centiles were 3.0/3.5/5.6 and 3.1/3.6/5.8 respectively
(Figure S2).
A. Definition of target INR range
Figure 1 shows cumulative frequency distributions for PoR (left
column) and PoT (right column), for PoR and PoTin control (solid
lines), PoR and PoTtoo high (dashed lines) and PoR and PoTtoo low
(dotted-dashed lines) for the three target INR ranges that were
considered. All measures were calculated across the whole period
of follow-up for individual participants. The better the anticoag-
ulant control, the further to the right the solid line should be, and
the further to the left of the panel the dashed, and dotted-dashed
lines, should be. As anticoagulant control deteriorates, the solid
line will move to the left and the other lines to the right. The
shallower the gradient of the lines, the greater is the variability in
anticoagulant control between individuals.
Not surprisingly, anticoagulant control appears best with the
widest target INR range I, worst with the most specific range III
and intermediate with range II. The magnitude of the differences
in the distributions for different target INR ranges is, perhaps, less
expected. For example, the median PoTin control for target INR
range I is 88%, 54% for range II, but only 28% for range III. For
all three INR ranges, participants were slightly more likely to have
an INR that was too high rather than too low, i.e. the dotted-
dashed lines lie consistently to the left of the dashed lines in all
panels of Figure 1.
B. Comparison of PoR and PoT measures of anticoagulant
control
The cumulative frequency distributions in Figure 1 for
measures based on PoR and PoT look remarkably similar.
Medians for the PoRin control and PoTin control for the three target
ranges were: 84% and 88% (panels A and D); 51% and 54%
(panels B and E); 29% and 28% (panels C and F). Medians for
PORtoo high and POTtoo high (11% and 8% for INR range I; 24%
and 24% for INR range II; 39% and 42% for INR range III), and
PORtoo low and POTtoo low (3% and 1% for INR range I; 19% and
14% for INR range II; 27% and 23% for INR range III) were also
Methods to Describe Anticoagulant Control
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similar. However, the figures show cumulative distributions across
all participants, so do not represent discrepancies between PoR
and PoT measures for individuals.
Discrepancies between PoR and PoT measures for individuals
are shown as Bland-Altman plots in Figure 2 for the target INR
range II, for PoR and PoTin control, PoR and PoTtoo high and PoR
and PoTtoo low. These graphs highlight that discrepancies for
individuals can range from 220% to +20%; the standard
deviations of the differences between PoT and PoR were about
7% for each pair of measurements. Note that the graphs show PoR
and PoT values when calculated across the whole period of follow-
up for individual participants; the discrepancies were substantially
larger between annual measures of PoR and PoT values, because
values were more dispersed. Figure S3 shows discrepancies as
Bland-Altman plots for the target INR ranges I and III.
There were statistically significant associations between the
difference and the average for all three plots, i.e. regression lines
fitted to the data had a positive gradient (all p,0.001). For PoR
and PoTin control, the fitted PoT value was greater than PoR (i.e.
positive difference, data point towards upper right quadrant of
panel in Figure 2A) above an average of 41% and smaller below
(i.e. negative difference, data point towards lower left quadrant).
For PoR and PoTtoo high andtoo low, the fitted PoT was also higher
than PoR for the majority of the range, above 24% and 40%
respectively.
C. Characterising the profile of anticoagulant control
The potential importance of considering whether the INR level
was too high or too low when out of range is illustrated in
Figure 3, which plots PoTtoo high against PoTtoo low for the three
target INR ranges considered. The distance of points furthest from
the origin depends on the median PoTtoo high and PoTtoo low, and
hence the target INR range. For example, with a wide target
range, when the medians for PoTtoo high and PoTtoo low are low,
the extreme values on each axis, and combinations of PoTtoo high
and PoTtoo low, will be constrained to be closer to the origin
(Figure 3A). Within the boundary formed by the most extreme
values, almost any combination of PoTtoo high and PoTtoo low
appears to be possible (Figure 3C).
A final issue concerns the period over which a measure of
anticoagulant control is aggregated. A decision about this should
depend on the precise hypothesis being investigated. Here, we seek
only to demonstrate that measures of anticoagulant control vary
over time. Therefore, aggregation over an increasing duration of
time will tend to obscure this variation. Table 1 illustrates the
extent to which annual measures of anticoagulant control change
from one year to the next, for the INR range II. The cells in the
table represent percentages of participants with anticoagulant
control classified as tabulated in consecutive years. (Participants
contribute multiple observations to this table because the
aggregate measure of anticoagulation control for yearn is
compared to aggregate measures of anticoagulation control for
both yearn21 and yearn+1.)
Changes between all categories were observed and only a
minority of pairs (34.5%, i.e. 2.6%+6.9%+19.2%+5.8%) had
PoTin control classified in the same ordinal category in successive
years (Table 1a). Classification of anticoagulant control in
successive years is not markedly more similar when the profile
measure of anticoagulant control is used (which takes into account
PoTtoo high and PoTtoo low); 42% of individuals had anticoagulant
control classified in the same category in successive years
(Table 1b). Agreement is somewhat better for PoTtoo high (52%)
and PoTtoo low (66%) (Tables S1a and S1b). The proportion of
measures of anticoagulant control classified in the same way in
successive years depends on the target INR range chosen. (Tables
for different target INR ranges are available from the authors.)
Discussion
Our findings show that choices about the target INR range and
the methods used for aggregating data about INR levels and
quantifying anticoagulant control all markedly influence the
derived values of anticoagulant control. Calculating aggregated
measures of anticoagulant control over long durations of follow-up
will inevitably obscure any association between anticoagulant
control and outcome over short periods of time. This is not an
academic matter since it is clear that researchers make different
choices about these factors [2–10].
Our findings arise from INR data collected in the context of a
randomised trial, which did not constrain usual management of
INR during follow-up and where the INR measurements did not
constitute an outcome. It is important to acknowledge that the
INR range to be analysed in a study should depend on the purpose
of the analysis. If the purpose is to audit the competence of
anticoagulation clinics (an administrative requirement), a narrower
range centred on the prescribed target INR for a particular
indication is appropriate. If the purpose is to relate INR control to
outcome measurements after valve replacement, such as throm-
boembolism, valve thrombosis, major bleeding and survival,
choosing a wider INR range may be more useful.
Strengths and limitations
Our dataset was relatively small but still included .27,000
individual INR readings and almost 3,500 person years of follow-
up. Collection of the data in the context of a RCT is an important
strength of the dataset. Participants in the trial had only one of two
types of prosthesis. Although the type of heart valve may interact
with the association between anticoagulant control and clinical
outcome [4], this does not limit the applicability of our
observations about measuring anticoagulant control. The distribu-
tion of INR readings in this study was very similar to that of
Cannegieter and colleagues [4] and slightly less dispersed than that
of Butchart and colleagues [3] In so much as self-monitoring
regimens for anticoagulant control achieve better control [6–8],
PoTin control with self-monitoring might be expected to be less
variable over time than observed with our data. However, since
INR readings still vary over time with self-monitoring, these
regimens would not change our findings with respect to different
target ranges and different methods of measuring anticoagulant
control.
The INR ranges that we considered relate to guidelines that
were contemporary with the data collection. Current guidelines
tend to recommend target INRs, e.g. 2.5 for AVR and 3.0 for
MVR, rather than target ranges, in order to avoid the extremes of
the ranges being considered equally acceptable by anticoagulation
clinics. However, any analysis of the adequacy of anticoagulation
control over time (as opposed to the INR target in an
anticoagulation clinic) still needs to set a range within which
Figure 1. Cumulative percentages of the proportion of readings (panels A, B and C) and follow-up time (panels D, E and F) in range,
too high and too low. Results are shown for the three different target INR ranges investigated: I - 2.0 to 4.0 (panels A and D); II - 2.5 to 3.5 (panels B
and E); III - 2.5 to 3.0 for the AVR and 3.0 to 3.5 for the MVR groups (panels C and F).
doi:10.1371/journal.pone.0098323.g001
Methods to Describe Anticoagulant Control
PLOS ONE | www.plosone.org 5 July 2014 | Volume 9 | Issue 7 | e98323
Figure 2. Limits of agreement plots comparing proportion of readings and proportion of time in range, too high and too low for
target INR range II (2.5 to 3.5). The long-dashed line represents the difference between the % of readings and the % of time; the short-dashed
line represents the 95% limits of agreement.
doi:10.1371/journal.pone.0098323.g002
Methods to Describe Anticoagulant Control
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control is considered satisfactory. To this extent, our findings are
as applicable now as they were during follow-up to the trial.
There were some gaps in the INR record for participants. Most
of these arose because of the way the data were collected and do
not affect the representativeness of the dataset. A small proportion
of INR readings (about 4%) were .56 days after the preceding
reading and within the sequence of the ‘‘last 10 measurements’’
collected at the annual follow-up. The distribution of time between
readings beyond 56 days formed a smooth tail and we have no
reason to suspect that omitting these periods of time could have
introduced bias.
Proportion of time versus proportion of readings within
the target range
Azar and colleagues, citing Duxbury, pointed out that PoRin
control may be biased if the number of readings per patient varies
and is correlated with anticoagulant control [9]. They compared
different methods for quantifying anticoagulant control, highlight-
ing that it is PoTin control rather than PoRin control that is important.
We completely concur with this view and recommend that
interpolating the INR level between readings should always be
used in future.
Azar and colleagues, based on a single target range (2.8 to 4.8)
found that PoRin control was consistently, and considerably, less
than PoTin control (63% and 77% overall, respectively). In contrast,
we found that medians for PoR and PoTin control were similar and
that neither was consistently larger. The difference between
medians was greatest (PoRin control being smaller) for the widest
target range investigated (2.0 to 4.0) and we suspect that the
direction of the difference depends on the target INR range used.
We believe that, as the PoTin control decreases, the difference
becomes smaller and reverses (PoRin control being larger) for very
‘strict’ target INR ranges; this view is supported by positive
gradients for regression lines (not shown) fitted to the scatter plots
in Figure 2.
Describing the proportion of time outside the target
range
Previous researchers have focused primarily on the PoTin control
or PoRin control for a specified target range [2,3,5,6,8,11].
However, the PoR or PoTtoo high/too low are also likely to be
important because different clinical events are associated with high
and low INR levels and any target INR range represents an
attempt to balance the competing risks of thromboembolic and
bleeding complications.
Although follow-up time can be divided into PoTin control,
PoTtoo high and PoTtoo low, only two can be modelled as
continuous variables at any one time because of the degrees of
freedom. Choices about how to model these variables (i.e. which
pair to include, whether to include quadratic terms, etc.) introduce
a further source of variation. These complexities led us to develop
the profile measure. Because observations are classified into
mutually exclusive categories, each category can be modelled
relative to ‘good’ control, in principle allowing the balance
between thromboembolic and bleeding risks to be investigated
directly. To the best of our knowledge, no similar measure has
been reported before.
Implications of different choices about measures of
anticoagulant control
At best, when researchers make different choices, it becomes
difficult or impossible to compare findings across studies and to
Figure 3. Plot of proportion of time too high and too low for target INR range I (2.0 to 4.0), INR range II (2.5 to 3.5) and INR range III
(2.5 to 3.0 for the AVR and 3.0 to 3.5 for the MVR groups).
doi:10.1371/journal.pone.0098323.g003
Table 1. Comparison of the classification of annual observations of anticoagulant control for INR range II for the same patients in
consecutive years; (a) the proportion of follow-up time (PoT)in control, (b) profile measure of anticoagulant control.
(a) PoTin control
Year(i+1)
Year(i) 0–24% 25–49% 50–74% 75–100% Total
0–24% 2.6 3.4 5.1 1.4 12.5
25–49% 4.1 6.9 9.8 4.9 25.7
50–74% 4.4 9.2 19.2 8.6 41.3
75–100% 1.4 4.2 9.1 5.8 20.6
Total 12.5 23.6 43.2 20.7 100.0
(b) Profile measure of anticoagulant control
Year(i+1)
Year(i) Too low Good Fair Too high Total
Too low 7.6 5.5 3.5 1.9 18.6
Good 4.4 11.4 5.1 8.7 29.7
Fair 3.4 5.0 6.8 5.6 20.7
Too high 2.1 7.7 5.4 15.9 31.0
Total 17.4 29.7 20.8 32.1 100.0
doi:10.1371/journal.pone.0098323.t001
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establish an evidence base for clinical practice. More worryingly,
in observational studies when choices vary systematically over time
and are confounded with changes in clinical practice (e.g. heart
valve design), it becomes difficult to distinguish whether differences
in research findings are attributable to changes in practice or to
different choices about measuring anticoagulant control. Other
complexities of comparing clinical outcomes across studies have
been described elsewhere [18].
The U-shaped function describing the risk between INR level
and adverse outcome related to anticoagulant control [4], and the
fact that INR target ranges are not centred on the same INR level
[2,3,5,11,14,15], makes researchers’ choices about measures of
anticoagulant control particularly critical. The profile measure of
anticoagulant control reported here would be expected to vary
considerably when target ranges are centred on different values
because of the way in which PoTtoo high and PoTtoo low will be
affected.
In RCTs, comparisons of anticoagulant control between groups
are completely valid, irrespective of the choices made. However,
the magnitude of differences observed, and their likely statistical
significance, can still be substantially affected by the precise
measures of anticoagulant control that are chosen.
Conclusions
Researchers’ choices about methods to derive measures of
anticoagulant control markedly influence the values ultimately
used for analysis. The use of different methods across studies
makes it difficult or impossible to compare findings and to establish
an evidence base for clinical practice. The obvious solution is to
standardise methods for quantifying anticoagulant control,
although it is less clear what standard should be adopted.
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